Search results
Results from the WOW.Com Content Network
performed at 12 months after the last patient had entered treatment.1 A total of 132 women were treated with abemaciclib monotherapy. All patients had a median of 5 lines of prior therapy for any setting, including a median of 3 lines of prior therapy for metastatic disease.8 Prior therapies in the metastatic setting included • ET (87.1%)
BACKGROUND Cyclin-dependent kinase 4 and 6 (CDK4 and 6) inhibitors have changed the treatment landscape of hormone receptor positive
Upon verification, healthcare professionals have access to Eli Lilly product information and professional resources.